about
From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resourceDevelopment of Human Membrane Transporters: Drug Disposition and PharmacogeneticsPharmacogenomics of chemotherapeutic susceptibility and toxicityCommon variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.Treatment of acute lymphoblastic leukemia from traditional chinese medicinePharmGKB: the Pharmacogenomics Knowledge Base.Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?The genetic architecture of methotrexate toxicity is similar in Drosophila melanogaster and humans.Mathematical modeling of folate metabolism.Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.Genome-Wide Screen Reveals sec21 Mutants of Saccharomyces cerevisiae Are Methotrexate-Resistant.Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate.Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Pharmacogenetics of childhood acute lymphoblastic leukemia.Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.Impact of Undernutrition on the Pharmacokinetics and Pharmacodynamics of Anticancer Drugs: A Literature Review.Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of MethotrexateSLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.An LC-MS chemical derivatization method for the measurement of five different one-carbon states of cellular tetrahydrofolate.Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models.Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.
P2860
Q24632079-C94B6EA8-22DA-453D-B666-B24A6F704626Q26786582-EB10490F-8207-464A-9410-441B7BB5B475Q27025558-5B379EAA-F5E7-42FE-B670-3F1F0391B10BQ30418239-F7CF2E50-EE2B-48ED-812B-275B7DAD693EQ33557148-31E12346-D026-4073-8B39-3AF59932E19CQ33632120-31A37F72-0C27-44B4-8E9F-AAABD62480F2Q33746550-D3F76AD4-C4B9-491B-8026-C601398296CFQ33855594-B207813B-3325-4351-A462-A57AA028E989Q33914131-22520A5C-E568-4EB4-AB6C-15029F962813Q35814091-F3DA45E4-F2FC-4D0A-AF4A-7879470FF862Q37079514-BC062711-B53E-4371-A302-BC0428F5CBC1Q37100917-B24581FA-95D8-4534-9250-1C72277B43A3Q37641721-C3315C8C-18ED-4937-BCDC-98B148FEAF83Q37746482-180951E8-C250-4639-A703-50088F8B5C0DQ38068540-6AA39AB4-9F03-47E2-871A-0D38DF59C673Q38238947-1CA8ED9F-22C3-4421-9C06-0665F0825C42Q38243175-166198D9-EA52-417A-97FC-990E3644E972Q38262203-D0F46722-EF4E-4460-876C-AD9D0A9AFDC4Q38809116-1410F259-E4BE-4B86-909B-5B15014CAD87Q38869469-354045EB-FD42-498E-9EFB-1F753350210DQ38886498-2A51D44B-BB67-43D1-BF13-2CE0FDB9F18EQ38888350-3DE9230B-E4E5-4049-A137-288FA5387D7EQ41068390-B1DCBAB8-1825-4BF5-838A-3518922D1B14Q41846508-4AECE971-AB3F-43CE-85B1-197CC2337E2AQ42199862-B9201F82-41B5-43CC-87E2-20BF9B78E6AEQ42706096-0DA7EC66-FD32-457F-BF41-44D2DF9CA23FQ46322512-93720FD7-7125-4A85-9C1C-2F449FB89190Q46446111-4E25D12D-0A4E-4FE3-A42D-3769C4A9E01AQ49527931-7BCA2A95-EAD6-49FF-8DCC-639FC48F7D78Q53093606-8B5A4B20-8B4C-4054-B485-E3BAEE7AD74D
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
PharmGKB summary: methotrexate pathway.
@ast
PharmGKB summary: methotrexate pathway.
@en
type
label
PharmGKB summary: methotrexate pathway.
@ast
PharmGKB summary: methotrexate pathway.
@en
prefLabel
PharmGKB summary: methotrexate pathway.
@ast
PharmGKB summary: methotrexate pathway.
@en
P2093
P2860
P50
P1476
PharmGKB summary: methotrexate pathway
@en
P2093
Caroline F Thorn
Cornelia M Ulrich
Deborah French
Howard L McLeod
James Steven Leeder
Kathy Giacomini
Mara L Becker
Mary V Relling
Russ B Altman
P2860
P304
P356
10.1097/FPC.0B013E328343DD93
P577
2011-10-01T00:00:00Z